Veterans Caught Between Policy Paralysis and Controversy in DC

OG article by Jack Gorsline

February 11, 2026

Veterans face ongoing challenges in accessing psychedelic therapies amid congressional debates, scandals, and policy delays. H.R. 7091, the Expanding Veterans’ Access to Emerging Treatments Act of 2026, introduced by Reps. Jack Bergman and Lou Correa, seeks permanent VA infrastructure for clinical trials on substances like psilocybin, MDMA, ibogaine, ketamine, and 5-MeO-DMT, plus compassionate-use protocols. Supporters highlight its role in addressing PTSD, TBI, and chronic pain where traditional treatments fail. The Freedom to Heal Act expands Right to Try access to Schedule I drugs post-Phase I trials for terminal or exhausted-option patients, but faces concerns over protocols and risks, with limited Senate support. Controversies include scandals tied to the "ibogaine lobby," such as assault charges against a veteran advocate and ethical questions around congressional staff involvement in treatments abroad. A veteran has requested oversight into potential conflicts in the psychedelic advocacy ecosystem. Advocates stress evidence-based, federally overseen paths to reduce risks like overseas travel, while calling for transparency to maintain bipartisan momentum and prioritize veteran mental health over profit-driven concerns.